Kornimate/medical-research-clean huggingface dataset:
the giraffe study: genomic risk markers for atrial fibrillation following extended cardiac rhythm monitoring

Conditions: Patients With Symptoms of Cardiac Arrhythmia at Risk for Atrial Fibrillation

Summary: our primary hypothesis is that a risk score comprised of approximately 10 single nucleotide polymorphisms (snps) that are associated with atrial fibrillation at the genome wide association study (gwas) level is associated with the development of atrial fibrillation among previously undiagnosed patients at high risk for atrial fibrillation. a current example of these snps is shown in table 1. as a secondary hypothesis, we will test the association between atrial fibrillation diagnosed in this study with a subset of snps reported to be associated with atrial fibrillation and with fine-mapping snps. we will also test the association between atrial fibrillation of less than and greater than 30 seconds and a panel of approximately 10 snps.


Eligibility criteria:
inclusion criteria: * symptoms of high clinical suspicion for atrial fibrillation prompting referral for ambulatory cardiac rhythm monitoring for potential atrial fibrillation. and * at high risk for atrial fibrillation, defined as any one of the following: ischemic stroke with no defined etiology (in prior 6 months) \[3, 4, 6, 7\], hypertension \[33\], increased body mass index (bmi \>30kg/m2) \[33\], heart failure \[33\], clinically significant murmur \[33\], prolonged pr interval on resting ecg \[33\], chronic kidney disease \[34\], hypertrophic cardiomyopathy \[35\], congenital heart disease \[36\], chronic obstructive pulmonary disease \[37, 38\], sleep apnea \[39-41\], thyroid disease \[42, 43\], family history of atrial fibrillation \[44\], diabetes \[45\] or excess alcohol consumption (male \> 14 drinks/week, female \>7 drinks/week)\[46\]. * age 40 years or older * capable of providing informed consent * capable of wearing a zio patch for up to 14 days * capable of providing a blood sample exclusion criteria: * previously documented atrial fibrillation or atrial flutter. * prior cardiac surgery (coronary artery bypass grafting, valve replacement or repair, pericardial stripping, etc) within the past 30 days. * hyperthyroidism. * have known skin allergies, conditions, or sensitivities (e.g. allergy to adhesives, psoriasis) as the zio patch should not be used on patients with known skin allergies, conditions, or sensitivities. * are receiving pacing therapy. * are anticipated to receive or require external cardiac defibrillation during the monitoring period. * are anticipated to have exposure to high frequency surgical equipment during the monitoring period.

Keywords: atrial fibrillation cardiac monitoring genomics
amnion bilayer and stem cell combination therapy on thin endometrium infertile patients

Conditions: Cell- and Tissue-Based Therapy

Summary: severe infections or trauma to the endometrial lining causes permanent scars that disrupt the menstrual cycle and lead to conceive failure. transplantation of biological graft seeded with stem cells is purposed to regenerate and recover the capability of the endometrial lining back into its cycles. initially, the techniques to isolate and culture the endometrial cells and amnion epithelial stem cells were developed, then the endometrial cells form patients with thin endometrium. tissue were obtained from hysteroscopic biopsy, weight between 100 µl, while up to 20 µl from the thin endometrium. tissue were digested using collagenase-1 and cultured using dmem-f12 added wit epidermal growth factor. endometrial cells will be characterized to ssud2, icam and brcp1. amnion epithelial stem cells (haesc) will be isolated using collagenase-1 and hyaluronidase. characterization towards tra-1-60, ssea-4, oct 3/4, and nanog. in the future, the cells will be co-culture on amnion bilayer, and stained using ihc against α-cadherin, estrogen receptor α, progesterone receptor. endometrial receptivity (hoxa10, lif (early secretory) adhesion, vegf, osteopontin (spp1) to indicate the pinopodes will be identified using qpcr.the spp1, target of mir424 expressed during the receptive phase.


Eligibility criteria:
inclusion criteria: * patients with thin endometrium without scar * patients with acute thin endometrium post-therapy (medicamentosa) * patients who are willing to participate in the study exclusion criteria: * patients with thin endometrium due to tb * patients with cancer in the reproductive system

Keywords: endometrial stem cells amnion epithelial stem cells amnion bilayer thin endometrium secondary amenorrhoe
clinical trial of pla2r-igg4 detection kit (time-resolved fluorescence immunoassay)

Conditions: Membranous Nephropathy - PLA2R Induced; Kidney Diseases-except Membranous Nephropathy

Summary: the goal of this observational clinical trial is to compare assessment reagents with clinical diagnostic criteria in patients with membranous nephropathy. the main questions it aims to answer are: * evaluating the sensitivity and specificity of the test reagent in the diagnosis of membranous nephropathy. * evaluating whether the clinical diagnostic performance of the test reagent meets the requirements for auxiliary diagnosis of membranous nephropathy. participants will provide approximately 4ml of blood. researchers will compare the levels of anti-pla2rigg4 in patients with membranous nephropathy and patients with other renal diseases,to see if there is a significant difference.


Eligibility criteria:
inclusion criteria: * pla2r-induced membranous nephropathy group 1. pathological examination showed that patients with membranous nephropathy were positive for pla2r by immunohistochemistry, and the symptoms were not completely relieved; (24 h urine protein quantification\<0.3g or urine protein /creatinine (upcr)\<300mg /g is regarded as complete remission) 2. in patients with nephrotic syndrome (serum albumin ≤ 30.0g /l, clinical manifestations show moderate to large amount of proteinuria (urine protein\>3.5g /l or urine protein /creatinine ratio ≥ 3500mg /g), and their serum anti pla2r antibody detection shows positive. * secondary membranous nephropathy group patients in nephrology department who have ruled out primary membranous nephropathy. the patient has the remaining serum samples of normal test, and the serum volume of the sample is not less than 1ml. exclusion criteria: 1. the amount of centrifuged serum sample after blood collection is less than 1ml or the amount of residual serum in normal test is less than 1ml; 2. non-serum samples, plasma samples; 3. patients with mental or cognitive disorders; 4. no samples with definite clinical diagnosis; 5. samples with incomplete information.
clinical trial on the prevention of thrombocytopenia after first-line chemotherapy

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: to assess the efficacy and safety of administration of rhtpo at different time in the treatment of thrombocytopenia caused by first-line gc/gp regimen for non small cell lung cancer (nsclc)

this is a randomized, controlled, open-labeled, multicenter clinical trial. the subjects are patients with nsclc who are going to receive gc/gp regimen chemotherapy. vadhan-raj et al conducted a study in which they administered rhtpo in various ways to patients with sarcoma receiving platinum-containing chemotherapy. the results demonstrated that timing of administration of rhtpo can be adjusted according to the occurrence time of nadir platelet values induced by chemotherapy. the timing of administration of rhtpo in this study was determined based on the above proofs.

Eligibility criteria:
inclusion criteria: 1. male or female patients at the age of 18 to 75 years old 2. histologically or cytologically diagnosed nsclc cases 3. thrombocytopenia occurred in the selected chemotherapy cycle confirmed by double test results with platelet count lower than 75×109/l 4. fit for chemotherapy (wbc ≥ 4.0×109/l；neutrophil count\> 1.5×109/l；plt ≥ 80×109/l；alt ≤ 3 times the upper limit of normal range；ast ≤ 3 times the upper limit of normal range；tbil ≤ twice the upper limit of normal range；ecog ps ≤ 2；without severe cardiopulmonary defects) 5. expected lifespan over 12 weeks 6. with understanding ability and voluntarily sign informed consent form 7. be able to comply with the study and follow-up process exclusion criteria: 1. with any unstable systemic diseases including active infection, uncontrolled hypertension, liver diseases, renal diseases or metabolic diseases 2. with uncontrolled brain metastasis symptoms (patients whose brain metastasis controlled over 4 weeks without hormone therapy can still be enrolled) 3. with heart cerebrovascular diseases, congestive heart failure with nyha above ii degree, with unstable angina pectoris, with acute myocardial infarction or cerebral infarction within 6 months 4. breast-feeding or pregnant women 5. platelet count over 300×109/l
australian trial in acute hepatitis c

Conditions: Hepatitis C

Summary: australian trial in acute hepatitis c (atahc) a prospective non-randomised dual arm longitudinal cohort of newly acquired hepatitis c infection into which participants will be enrolled and then followed at 3 monthly intervals over a 3 year period. all participants will be offered a 24 week course of pegylated interferon alfa 2a which will be commenced within 12 weeks of screening (patients coinfected with hiv will be offered 24 weeks with pegylated interferon alfa 2a plus ribavirin).

the main purposes of the study are: * to enrol and follow-up a large group of people with acute hepatitis c infection to examine why some people naturally clear hepatitis c and some don't. * to examine how many people become re-infected after having cleared hepatitis c and to look at why this happened. the study will also offer everyone taking part the option of undergoing a 6 month course of pegylated interferon alfa 2a (plus ribavirin if hiv coinfected) as treatment for hepatitis c. the purpose of this part of the study is: 1. to examine whether treatment is effective in clearing the virus.

Eligibility criteria:
inclusion criteria: * male and female patients \>16 years of age; anti-hcv antibody positive within the previous 6 months; anti-hcv antibody negative in the two years prior to the anti-hcv antibody positive result or acute hepatitis (jaundice or alt \> 10 xuln) within the 12 months prior to the anti-hcv antibody results (where other causes of acute hepatitis are excluded); hcv rna positive (for treatment group); negative urine or blood pregnancy test (for women of childbearing potential; treated arm only); informed consent exclusion criteria: * women with ongoing pregnancy or breast feeding;therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) \ 1.5 times the upper limit of normal at screening; hgb\< 12g/dl in women or \< 13g/dl in men at screening (for patients who receive combination therapy with pegylated interferon and ribavirin only); male partners of women who are pregnant (for patients who receive combination therapy with pegylated interferon and ribavirin only); history of a severe seizure disorder or current anticonvulsant use; history of immunologically mediated disease, chronic pulmonary disease associated with functional limitation, severe cardiac disease, major organ transplantation or other evidence of severe illness, malignancy, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study; history of thyroid disease poorly controlled on prescribed medications, elevated thyroid stimulating hormone (tsh) concentrations with elevation of antibodies to thyroid peroxidase and any clinical manifestations of thyroid disease; evidence of severe retinopathy (e.g. cmv retinitis, macula degeneration); inability or unwillingness to provide informed consent or abide by the requirements of the study

Keywords: acute hepatitis c
pronase improves efficacy of chromoendoscopy screening on esophageal cancer

Conditions: Esophageal Neoplasms

Summary: lugol's solution staining was regarded as a gold standard to detect early superficial lesion during esophageal cancer screening using endoscopy. however, the sensitivity and specificity were influenced by mucus and food debris of esophagus. pronase, a kind of protease, was previously shown to improve the visibility of gastrointestinal tract. it's unknown if the pre-treatment with pronase would also improve the quality of iodine staining in esophagus.a randomized double-blind clinical trial was designed to investigate whether or not pronase might improve detection rate of early esophageal lesion, especially high grade dysplasia and early cancer by improving the esophageal visibility.


Eligibility criteria:
inclusion criteria: * patients 60 years to 75 years old * patients less than 60 years old, but with one or multiple high risk factors for esophageal cancer including smoking and drinking addiction,family history of esophageal cancer, personal history of esophageal or head and neck malignancies, previous endoscopy documenting iodine void superficial lesion. exclusion criteria: * allergy to iodine or any other medicine which used in this trial. * previous endoscopy revealing advanced esophageal cancer or other non-superficial lesions. * conditions interfering visibility of endoscope including gastrointestinal obstruction and upper gastrointestinal bleeding. * anatomic variation by surgery. * pregnancy * other conditions which investigator consider the patient at high risk for complications.

Keywords: esophageal neoplasms lugol's solution pronase endoscopy, digestive system pretreatment method
study of an investigational drug, ro7239361 (bms-986089), in ambulatory boys with dmd

Conditions: Muscular Dystrophy (DMD)

Summary: the purpose of this study is to determine the safety and tolerability of ro7239361 in boys with duchenne muscular dystrophy with any genetic mutation.


Eligibility criteria:
inclusion criteria: * diagnosed with dmd * able to walk without assistance * able to walk up 4 stairs in 8 seconds or less * weigh at least 15 kg * taking corticosteroids for dmd exclusion criteria: * ejection fraction \< 55% on echocardiogram, based on central read * any behavior or mental issue that will affect the ability to complete the required study procedures * previously or currently taking medications like androgens or human growth hormone * use of a ventilator during the day * unable to have blood samples collected or receive an injection under the skin * treatment with exon skipping therapies 6 months prior to study start * treatment with ataluren or any investigational drug currently or within 5 half-lives prior to study start
the acute effect of two berry extracts on cognition and mood in adults aged 40 to 60

Conditions: Ageing

Summary: the first study of my phd showed that acute supplementation of berry extracts can modulate cognitive behaviour in healthy adults. there is a growing body of evidence supporting an improvement in memory and learning performance in animal models following the ingestion of flavonoid rich fruits (shukitt-hale et al 2008;spencer 2008; spencer et al., 2008). however, study 2, showed no effect on any aspects of memory in healthy young adults after supplementation of the berry extracts. it is hypothesised that the lack of behavioural effects on memory of the berry juice in study 2 was because of the cohort used. these healthy adult participants were already performing near to their peak (salthouse et al., 2009), and unlike study one, participants were not mentally fatigued enough to reveal subtle cognitive benefits. the aims of the study are to examine if acute supplementation of two berry extracts in an older population can augment memory, attention and executive function. secondly, the time course of these behavioural effects will be measured by multiple cognitive assessments throughout the day after consumption of the extracts.


Eligibility criteria:
inclusion criteria: * healthy * non-smokers * aged between 40 and 60 years exclusion criteria: * history of neurological, vascular or psychiatric illness. * bmi greater than 35 kg/m2 * current diagnosis of depression and/or anxiety. * history or current diagnosis of drug/alcohol abuse. * anaemia. * any heart disorder. * hypertension * any respiratory disorder. * diabetes. * food intolerances/sensitivities. * phenylketonuria. * use tobacco products or have ceased in the last 6 months. * currently taking, or have taken in the last 2 weeks, any prescribed, illicit or herbal drugs and food supplements. * any known active infections. * hiv antibody positive. * currently have, have ever had, or may be at risk of hepatitis. * have suffered from jaundice within the last year. * have haemophilia or any similar clotting disorder. * history of head trauma * history of migraines * history of learning difficulties * any issues with giving blood samples.
genetic expression alteration affect on lateral neck node metastasis of thyroid papillary microcarcinoma : microarray analysis

Conditions: Papillary Thyroid Microcarcinoma

Summary: in this study, the investigators look at the genetic expressional alteration which influenced on the early lateral neck node metastasis in thyroid papillary microcarcinoma.

papillary thyroid carcinomas (ptcs) measuring 1.0 cm or less in diameter were defined as papillary thyroid microcarcinomas (ptmcs) by the world health organization (who), emphasizing on their benign behavior, probably of little clinical significance, which do not affect patients' survival. however, some reported that ptmcs may have aggressive behavior, can cause locoregional recurrences, cervical lymph node metastases, and even distant metastases. but till now, the characteristics of ptmcs with early lateral neck node metastasis were only reviewed and described by the clinicopathological parameters, and no analysis of ptmcs by the gene level is available. in these study, we investigate the genetic expressional alteration which influenced on the early lateral neck node metastasis in thyroid papillary microcarcinoma.

Eligibility criteria:
inclusion criteria: * age≥20 years old * conventional type papillary thyroid microcarcinoma (0.5cm≤tumor size≤1.0cm) * group 1: no lymph node metastasis /group 2: with lateral neck node metastasis exclusion criteria: * tumor with capsular invasion (t3 tumor) * distant metastasis * combined underlying thyroiditis
strong program for cancer patients

Conditions: Gastrointestinal Cancer

Summary: the purpose of the study is to assess the feasibility and participant satisfaction with the support through remote observation and nutrition guidance (strong) program. the program provides nutrition support for participants living with gastrointestinal cancer who are receiving chemotherapy and surgical treatment.


Eligibility criteria:
inclusion criteria: * gastrointestinal cancer diagnosis (e.g., colon cancer, appendiceal cancer) * peritoneal disease diagnosis * received cytoreductive surgery and heated intra-peritoneal chemotherapy (crs-hipec) for curative intent at moffitt * transitioned to an oral diet post-surgery * able to speak and read english * able to provide informed consent exclusion criteria: * documented or observable psychiatric or neurological disorder that would interfere with study participation (e.g., psychosis, active substance abuse) * undergoing concurrent treatment for a secondary primary cancer * receipt of parenteral or enteral nutrition after surgery
implementation of onsite, rapid art initiation among people who inject drugs living with hiv at syringe services program

Conditions: Harm Reduction; HIV Infections; Drug Use

Summary: the purpose of this study is to see if providing hiv medicine right away at the idea syringe services program will help the participant start and remain in hiv care, including having no detectable hiv in the participant's blood.


Eligibility criteria:
inclusion criteria: 1. adult (age\>18 years); 2. positive rapid hiv test; 3. ability to provide informed consent; 4. hiv rna \> 200 copies/ml; 5. creatinine clearance \> 30 mg/dl as measured by serum creatinine; 6. no allergy to bictegravir/emtricitabine/tenofovir alafenamide (bftaf) as indicated by patient history and self-reported allergies. exclusion criteria: 1) any other comorbidities at the discretion of the investigator
study 15 - comparing gemcitabine/carboplatin and hydroxychloroquine versus carboplatin/etoposide therapy alone in small cell lung cancer (sclc)

Conditions: Small Cell Lung Cancer

Summary: to determine whether the combination of gemcitabine/carboplatin with hydroxychloroquine (hcq) is associated with an improved clinical outcome (progression free and overall survival) compared with chemotherapy alone in patients with small cell lung cancer (sclc)

this is a multicentre, randomised, phase ii trial which aims to compare the combination of hydroxychloroquine and gemcitabine/carboplatin versus standard carboplatin/etoposide chemotherapy, as first line treat in patients with stage iv disease. the standard first line chemotherapy treatment remains a platinum-based chemotherapy and this has been unchanged for 20 years. novel active treatment approaches are urgently needed to improve survival in sclc. patients are randomised to one of two treatment arms; carboplatin/etoposide or gemcitabine/carboplatin/hydroxychloroquine.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed sclc * stage iv disease * performance status ecog 0-2 * life expectancy \>8 weeks * age 18 or over * willing and able to give informed consent * patient considered able to tolerate chemotherapy * adequate renal function - defined by gfr ≥50ml/min as measured by edta or c\&g * adequate bone marrow reserve: absolute neutrophil count ≥1.5 x 109/l, haemoglobin ≥90 g/l, platelet count ≥100 x 109/l * negative pregnancy test for wcbp * highly effective contraception is mandatory for all patients of reproductive potential * at least one site of measurable disease (target lesion) for recist 1.1 evaluation * hypersensitivity or history of severe allergic reaction to any of the imps * able to swallow medication exclusion criteria: * mixed cell histology (i.e. nsclc and sclc) * prior macular degeneration or diabetic retinopathy * history of glaucoma * patients with abnormal lfts (alp, alt/ast\*) that are ≥3 x uln (≥5 x uln for patients with liver metastases) * patients with abnormal bilirubin levels that are ≥1.5 x uln * prior treatment for this disease e.g. chemotherapy, surgery, radiotherapy (except palliative radiotherapy to bone metastases) * documented side effects to chloroquine or related agents * treatment with chloroquine or related agents within the last year prior to randomisation * evidence of significant medical condition or laboratory finding which, in the opinion of the investigator, makes it undesirable for the patient to participate in the trial * previous medical history of prolonged qt interval * a history of prior malignant tumour, unless the patient has been without evidence of disease for at least 3 years or the tumour was a non-melanoma skin tumour or early cervical cancer * patients with symptomatic brain metastases * women who are breastfeeding * concurrent cytochrome p450 enzyme-inducing anticonvulsant drugs e.g. phenytoin, carbamazepine, phenobarbital, primidone or oxcarbazepine * patients who are unable to have their digoxin levels regularly monitored * if both alt and ast performed then both need to be recorded